Glenview Trust Co Acquires Shares of 4,484 Stryker Corporation $SYK

Glenview Trust Co bought a new position in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,484 shares of the medical technology company’s stock, valued at approximately $1,412,000.

Several other hedge funds have also modified their holdings of SYK. Norges Bank acquired a new position in Stryker during the 4th quarter worth $1,822,272,000. Bank of America Corp DE bought a new position in Stryker in the 2nd quarter valued at $1,404,284,000. Auto Owners Insurance Co increased its stake in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Legal & General Group Plc bought a new stake in shares of Stryker during the second quarter worth $707,212,000. Finally, Jupiter Topco LLC bought a new stake in shares of Stryker during the second quarter worth $681,581,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 in the last 90 days. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SYK shares. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. JPMorgan Chase & Co. dropped their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Up 2.9%

Shares of Stryker stock opened at $331.32 on Friday. The business has a fifty day simple moving average of $329.10 and a 200 day simple moving average of $331.47. The stock has a market cap of $127.08 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.